Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (The MAMBO Study) Phase I

NCT06503848 is registered in ClinicalTrials.gov with Hospital Universitari Vall d'Hebron Research Institute as lead sponsor.

NCT NCT06503848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06503848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (The MAMBO Study) Phase I
Lead sponsor
Hospital Universitari Vall d'Hebron Research Institute
Phase
Observational
Overall status
Recruiting
Start date
January 25, 2024
Completion date
December 31, 2024
Enrollment
108 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

migraine disorders